# Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.

> **NCT00417820** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 35 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BCT194

## Key facts

- **NCT ID:** NCT00417820
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2007-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417820, "Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00417820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*